Samples / GLPI-103 / tmf/TMF-004_dsmb_charter.md

Data Safety Monitoring Board (DSMB) Charter — GLPI103-301

Field Value
Document ID TMF-DSMB
Version 2.0 (full)
Study No. GLPI103-301
Standard FDA DMC guidance; EMA; ICH E6(R3)
Confidentiality Confidential — TMF

Change History

Version Date Author Summary
1.0 2026-06-29 Clinical / PV Initial charter
2.0 2026-06-29 Clinical / PV Full charter — composition, procedures, data flow, stopping guidance

1. Purpose

The DSMB (IDMC) is an independent body that periodically reviews accumulating unblinded safety data (and any interim efficacy) to protect participants and study integrity.

2. Composition & Independence

≥3 voting independent members: an endocrinologist/diabetologist, a cardiologist (mechanism-relevant), and an independent biostatistician; a voting Chair. Members have no financial/intellectual conflicts and are independent of the sponsor study team. An independent unblinded statistician (not a board member) prepares closed reports.

3. Responsibilities

4. Meetings & Data Flow

Organizational meeting before first subject; safety reviews at predefined enrollment/exposure milestones (e.g., ~25%, 50%, 75% enrolled) and ad hoc for emerging signals. Open session (sponsor may attend) + closed session (unblinded; board + independent statistician only). Recommendations are minuted (TMF-DSMB-MIN).

5. Stopping Guidance

Considerations for unacceptable safety (e.g., excess SAEs, pancreatitis cluster, cardiovascular signal, severe hypoglycaemia imbalance). Any interim efficacy/futility would use pre-specified statistical boundaries (alpha spending; SAP-301 §11). Recommendations are advisory to the sponsor.

6. Confidentiality & Records

Members maintain strict confidentiality; unblinded outputs are restricted; minutes (open/closed) are retained in the TMF. Operating procedures and quorum (majority; Chair tie-break) are defined herein.